Company intelligence / Profile preview

Neurokappa Therapeutics

Philadelphia, Pennsylvania, United Statesneurokor.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Safety and tolerability of Salvinorin A has been observed in 6 human clinical trials with 80 participants, including a 30-patient double-blind, placebo-controlled, randomized study over 8 weeks showing no dose-related effects on BP and HR, no significant adverse events, and no evidence of persisting effects at 1-month follow-up[1]

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

ANVS-401

Phase 2

Indications: Alzheimer's disease, Parkinson's disease, Down syndrome-associated Alzheimer's disease

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neurokappa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurokappa Therapeutics.

Explore the full profile